TX-MAVENIR
21.7.2021 15:02:12 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud infrastructure and transforms the way the world connects, today announced its Business Support System (BSS) solution called Mavenir Digital Enablement (MDE) platform. The MDE Platform enables Communications Service Providers (CSPs) to quickly and easily build new digital offerings through a simplified graphical service experience creator. MDE can be deployed either as a standalone BSS or as an overlay on the CSP’s legacy BSS.
This solution uses a proven Microservices, API-first, Cloud-Native, Headless (MACH) architecture that is aligned with TM Forum’s Open Digital Architecture (ODA) and OpenAPIs . Its low/no-code UI enables agile experience creation. With a unified product catalog, MDE lets CSPs easily develop and deploy new services, speeding both time to market and time to revenue. The solution also provides tools for consolidation and transformation of network usage and non-usage data, which generates insightful information to help deliver hyper-personalized services and offerings through an omnichannel experience.
Mavenir’s unique technology enables a “composable” BSS architecture so CSPs can design their own BSS solution by assembling the right mix of microservices from the MDE library. It is designed to help CSPs innovate fearlessly without being restricted by the inflexibility of legacy BSS or IT systems. It also enables them to leverage their existing BSS/IT infrastructure by deploying the MDE Marketplace as an overlay solution. Use cases include:
- Delivering greenfield MNO services
- Enabling a digital marketplace for bundling CSP services with partner services to generate new revenue streams
- Introducing a sub-brand in response to digital attacker brands or to address a niche segment of the market
- Launching a new MVNO service by utilizing the MDE BSS as a Mobile Virtual Network Enabler (MVNE)
The MDE BSS platform can quickly and easily be deployed as an adjunct solution to launch new business services such as:
- 5G FWA/eMBB/AR/VR services
- IoT services for B2C/B2B/B2B2X customers
- Connectivity bundles for B2B customers
- Unified communication (UCC) and contact center for B2B customers
- Rich Business Messaging using RCS for B2B customers
“Mavenir’s MDE platform enables CSPs to deliver the promise of 5G and speed up the return on their 5G investments by eliminating perpetually slow processes and the barriers of cost and time from legacy BSS,” said BG Kumar, President Communications Services at Mavenir. “Through its open APIs, MDE easily integrates with existing IT or BSS systems and can run as an overlay solution, giving CSPs the option to escape existing vendor lock-in and freedom from development limitations on legacy IT systems.”
The solution is currently deployed with various CSPs in APAC, Europe, and the Americas.
Supporting documents:
- MDE Webpage
- MDE Solutions Brief
- MDE White Paper: Five Steps to a Digital Telecom Marketplace
- MDE Video
- Mavenir's Cloudified Portfolio Press Release
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom